Skip to content

Operating margin at other companies

CytomX Therapeutics logo
CytomX TherapeuticsCTMX
-181.9%-206pp
Immunome logo
ImmunomeIMNM
-5,947.9%-12,002pp
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-543.9%-271pp
Lantheus Holdings logo
Lantheus HoldingsLNTH
18.8%-10.7pp
uniQure logo
uniQureQURE
-1,059.7%+380pp
Precigen logo
PrecigenPGEN
-2,890.9%

Other financials

Income statement

See full
Revenue$2.2M+27.3%
Gross profit$738.0K+78.3%
Operating income-$28.3M-29.5%
Net income-$26.2M-44.1%
EPS (diluted)-$0.250.0%

Balance sheet

See full
Cash & equivalents$54.0M+21.5%
Total debt$4.2M+10.9%
Total equity$347.4M+22.1%
Total assets$410.8M+24.7%

Cash flow

See full
Operating cash flow-$31.5M-45.8%
CapEx$6.9M+47.3%
Free cash flow-$38.3M-46.1%

Valuation

See full
Market cap$342.14M+33.2%
Enterprise value$292.34M+35.2%
P/S34.2×+19.6×

Profitability

See full
Gross margin33.1%-7.1pp
Net margin-218.4%-781pp
FCF margin-1,073.3%

Returns & leverage

See full
Return on equity-35.2%+2.3pp
Debt / equity0.0×
Current ratio8.7×-8.3×

Where this comes from

Calculated from Perspective Therapeutics’s reported figures.

Based on trailing twelve months.

The official record: Perspective Therapeutics’s 10-Q, filed November 12, 2024, on SEC EDGAR. View the filing →

Ask your AI about Perspective Therapeutics's operating margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Perspective Therapeutics's operating margin?
Perspective Therapeutics (CATX) reported operating margin of -292.7% in Q3 2023.
How has Perspective Therapeutics's operating margin changed year-over-year?
Perspective Therapeutics's operating margin decreased by 212.2% year-over-year, from -93.7% to -292.7%.
What does operating margin mean?
Operating income as a percentage of revenue (trailing twelve months). Captures profitability from core operations after both cost of revenue and operating expenses, but before interest and taxes.